Insect-borne diseases Archives

In Depth 25 Apr 2023

What are biotech companies doing to tackle malaria?

The bite of an infected female Anopheles mosquito abets the entry of Plasmodium sporozoites in the bloodstream of humans, marking the beginning of the parasite’s life cycle. The sporozoites then travel to the liver and multiply, following which they invade red blood cells, proliferating in numbers yet again. And in about a week or two, malaria, […]

April 25, 2023 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 17 Apr 2023

Ghana becomes first country to approve University of Oxford malaria vaccine

Ghana has granted full national licensure for the University of Oxford’s R21/Matrix-M malaria vaccine, marking the first regulatory clearance for the vaccine for use in any country. Developed by the University of Oxford, leveraging Novavax’s adjuvant technology, and manufactured and scaled up by the Serum Institute of India PvT Ltd (SIIPL), the vaccine has been […]

April 17, 2023 - 4 minutesmins - By Willow Shah-Neville

News and Trends 4 Oct 2022

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Sep 2022

Fight against malaria boosted by findings from a vaccine trial showing high efficacy

Hope that malaria could be eradicated forever has been given a boost after new findings from a vaccine trial showed a high-rate of efficacy. Researchers from the University of Oxford and their partners have yesterday (September 8) reported new findings from their malaria vaccine R21/Matrix-M phase 2b trials following the administration of a booster dose. […]

September 9, 2022 - 4 minutesmins - By Liza Laws

News and Trends 7 Sep 2022

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Manus Bio receives additional funding to fight malaria with biotech

U.S. biomanufacturer Manus Bio has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial drug, artemisinin. The $2 million award will enable Manus Bio to begin scaling up the biological process it has developed towards the chemical intermediate, dihydroartemisinic acid. Economical and scalable […]

September 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever

A Belgian university spinoff has generated the biggest seed capital financing in the institution’s history. Closing with €30 million ($30 million), AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

In Depth 2 Aug 2022

The evolving arsenal against mosquito-borne diseases

Genetic engineering is breaking new ground in the control of mosquito-borne diseases. However, a genetic engineering approach isn’t the only option, as many biotech companies aim to prove. As the global climate continues to warm, disease-spreading mosquitoes such as Aedes aegypti are expected to establish themselves in the U.S. and Europe. This could result in […]

August 2, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 1 Jul 2022

Companies come together in fight against Dengue Fever

A vaccine to treat dengue fever, the mosquito-borne disease, is the end goal of two companies who have signed an agreement to produce and commercialize a lead candidate in the fight against the disease. Emergex Vaccines Holding Limited, a clinical-stage biotech company, recently announced that it has agreed a collaboration with the Molecular Biology Institute […]

July 1, 2022 - 4 minutesmins - By Liza Laws

News and Trends 24 Jun 2022

Covid and malaria vaccines on track for mass production in Rwanda

Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […]

June 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 9 Jan 2020

Emergex Vaccines Secures €10M to Advance Synthetic Vaccine Development

The UK biotech Emergex Vaccines has raised over €9.9M in a Series A funding round, which will allow it to progress the development of vaccines against diseases such as dengue, influenza, and Ebola to phase I clinical trials. Emergex specializes in the development of ‘set-point’ vaccines, which company CEO and co-founder Thomas Rademacher describes as […]

January 9, 2020 - 3 minutesmins - By External Contributor

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […]

November 18, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us